T. Hasegawa Co., Ltd. Overview
T. Hasegawa is Japan's second-largest flavour and fragrance (F&F) house and the world's tenth-largest by the company's own estimate, with FY2025 consolidated net sales of ¥73.5 billion (≈US$491 million). Unlike diversified peers, it is a near pure-play in high value-added compounded flavours, which generated 89.6% of FY2025 sales, with fragrances making up the balance; it does not sell commodity aroma chemicals externally at scale. The model is built on a large library of proprietary formulas developed by flavourists and perfumers (roughly a decade to train), high-mix manufacturing of about 12,000 products a year, and deep integration with Japanese beverage, dairy, snack, instant-noodle and seasoning makers. Its three-pole footprint — Japan (earnings base), China/Southeast Asia (high-margin growth) and the USA (scale-building via M&A) — is underpinned by a fortress balance sheet (83.5% equity ratio, effectively no debt). The principal debate is capital efficiency: ROE of 5.7% and a P/B near 1.0x.
What the company does
T. Hasegawa researches, develops, manufactures and sells flavours (food and beverage aromas) and fragrances (scents for cosmetics, toiletries and household products). Its upstream capabilities include synthesis of aroma chemicals, extraction of natural aromatics (including supercritical CO2 extraction at Fukaya since 1989), and analysis; the commercial output is overwhelmingly compounded products — formulations created to a customer's brief by blending natural and synthetic materials. Product formats span liquid compounded flavours, emulsified flavours, powdered flavours, natural extracts, processed fruit products and natural colourants [HIST], [MHLW-ITAKURA].
Company's own description (paraphrased from FY2025 disclosures)
In its FY2025 results and Securities Report, the company describes itself as a group that manufactures and sells various flavours and fragrances, giving primary weight to quality control and product safety, continually improving research and technology development, and concentrating on unique, high-quality, high value-added products. It frames its long-term mission as enriching lifestyles and contributing to a sustainable society through aroma and adjacent technologies [TANSHIN-FY25], [PRES-H1FY26].
Independent characterisation
T. Hasegawa is a mid-cap, B2B specialty-ingredients business whose economic moat rests on three things: (1) formula IP and tacit know-how embedded in its flavourists' libraries, which creates switching costs once a flavour is specified into a customer's SKU; (2) co-development intimacy with Japanese consumer-goods companies, where it holds an 18.8% share of the domestic top-10 F&F market; and (3) regulatory and quality infrastructure (FSSC 22000, ISO 9001) required by food majors [PRES-H1FY26], [SR-2025]. Its weakness relative to the global "Big Four" is scale: it lacks the global key-account "core list" status that multinationals use to restrict suppliers, which is why its overseas growth is concentrated in China, Southeast Asia and mid-sized US accounts rather than global FMCG majors.
Revenue model
| Revenue model element | Description | Share / evidence |
|---|---|---|
| Product sales (point-in-time) | Custom and catalogue flavours and fragrances sold per kg/lot to manufacturers; revenue recognised at transfer of goods | ~100% of revenue; the segment note states revenue is mainly goods transferred at a point in time [TANSHIN-FY25] |
| Services | Application development, sensory evaluation, trend reports — bundled into product pricing, not separately billed | — |
| Subscription / licensing | None disclosed | 0% |
| Processed food materials | Nut and fruit processing (Hasegawa Business Service's FC division) — small | Included in flavour sales; not separately disclosed |
Value-chain position
T. Hasegawa sits in the middle of the food and personal-care value chain: it buys essential oils, botanicals, petrochemical-derived solvents and aroma chemicals, adds formulation IP and processing, and sells to branded consumer-goods manufacturers. It is invisible to consumers. Pricing power derives from small ticket size relative to the customer's final product cost (flavour is a low single-digit share of a beverage's COGS) combined with high reformulation risk for the customer.
Customer types and end-markets
| Region | Flavour focus | Fragrance focus |
|---|---|---|
| Japan | Broad beverage and food usage; raw-material replacement flavours; health/medical foods | Cosmetics, household; odour masking; environmentally friendly fragrances |
| USA | Savoury, beverage, health; sweet flavours (Mission); Midwest via ABELEI | Not entered |
| China | Beverages and instant noodles; international and local customers | Household products (toiletry makers) |
| Southeast Asia | Flavour powders and beverage flavours; Vietnam PMI; Philippines expansion | Body care, served by exports from Japan |
Source: [PRES-H1FY26]. The equivalent FY2024 split was beverages ~33%, dairy ~24%, snacks ~12%, seasonings ~11%, instant noodles ~9%, other ~11% [PRES-FY24]. Beverage exposure makes sales seasonal (stronger in the second half) and sensitive to summer weather.
Regional end-market emphasis per management's portfolio map [PRES-H1FY26]:
No single customer exceeds 10% of consolidated sales [TANSHIN-FY25].
Strategy
Stated strategy (themes from the medium-term plan and briefing materials)
The management policy rests on three basic strategies: (1) expand the compounded flavours and fragrances business; (2) secure profits in the Japanese market; and (3) grow in overseas markets. These are supported by focus areas: strengthening proposal (solution-selling) capability, reform through "concentration and selection," accelerating overseas expansion via capex and M&A, building an organisation that takes on challenges, enhancing human resources (development plus mid-career hiring), and strengthening sustainability [PRES-H1FY26]. The overarching purpose is to deliver abundant, healthy living through aroma and contribute to a sustainable society. The medium-term three-year plan is a rolling plan revised every year [PRES-H1FY26].
Strategic initiatives (last 24 months)
| Initiative | Region | Detail / target | Status | Source |
|---|---|---|---|---|
| ABELEI acquisition and PMI | USA | ¥6.85bn; Midwest/East Coast channel; PMI completed by end FY2025 | Complete; ABELEI breakeven FY2025 | [PRES-FY24], [PRES-FY25] |
| US profit restoration | USA | Plant restructuring, new capacity, cost project (inspection, transport, packaging); "Bridge to Tokyo Phase 3" transfer of Japanese technology; target OP US$0.1M (FY2026) → US$2.3M (FY2027) → US$3.3M (FY2028) | In progress; H1 FY2026 loss narrowed to US$1.3M | [PRES-H1FY26] |
| US second plant (California), phase 3 | USA | ¥2.4bn over FY2026–FY2028 | In progress | [PRES-H1FY26] |
| Pinghu third China plant | China | ¥6.5bn over FY2026–FY2027; doubles China flavour capacity | Construction; start FY2027 | [PRES-H1FY26], [PRES-FY24] |
| Suzhou powder facility | China | New flavour-powder line | Installation; start FY2027 | [PRES-H1FY26] |
| Malaysia Enstek new plant | SE Asia | ¥4.8bn three-year spend; Halal and Asian demand | Construction; start FY2027 | [PRES-H1FY26] |
| Hoàng Anh acquisition and PMI | Vietnam | VND725bn (≈¥4.4bn); goodwill ¥3,682M (provisional); PMI completion December 2026 | Consolidated January 2026 | [PRES-H1FY26] |
| Fukaya plant project | Japan | ¥7.8bn FY2027–FY2028; production DX office | Planning | [PRES-H1FY26] |
| DX and IT reform (ERP) | Japan | ¥4.1bn over FY2026–FY2028 (¥2.8bn spent to FY2025) | In progress | [PRES-H1FY26] |
| Business Solution Division | Japan | Integrates sales, research and marketing for solution selling | Ongoing | [PRES-H1FY26] |
| Raw-material replacement and alt-protein | Japan | Flavours to replace scarce food materials; DAIZ alliance | Ongoing | [PRES-FY24] |
| Human capital management | Group | New HR system (FY2023), engagement survey, in-house business school, KPIs on women, mid-career and foreign managers | Ongoing | [PRES-H1FY26] |
| Capital policy reform | Group | DOE ≥3% from FY2026; FY2026 DPS ¥100; buybacks if PBR conditions met; cross-shareholding reduction to <10% of net assets | Adopted Nov 2025 | [TANSHIN-FY25], [PRES-H1FY26] |
| Restricted stock compensation | Group | Replaces stock options from FY2026 | Approved Dec 2025 | [TANSHIN-FY25] |
| SBTi near-term targets | Group | Scope 1+2 –58.8% by 2034 vs 2024 | Validated Sep 2025 | [SBT-PR] |
Medium-term financial plan (May 2026 version)
| Metric (JPY Mn) | FY2025 actual | FY2026 plan | FY2027 plan | FY2028 plan |
|---|---|---|---|---|
| Net sales | 73,495 | 76,500 | 79,500 | 82,400 |
| Gross profit | 30,347 | 32,310 | 33,100 | 33,960 |
| SG&A | 21,832 | 22,880 | 23,600 | 24,360 |
| Operating profit | 8,515 | 9,430 | 9,500 | 9,600 |
| Ordinary profit | 9,288 | 10,050 | 9,860 | 9,910 |
| Net profit attributable | 6,921 | 7,320 | 7,100 | 7,150 |
| EBITDA | 13,938 | 15,157 | 15,869 | 16,377 |
| Capital investment | 5,164 | 13,541 | 14,146 | 9,169 |
| R&D expenses | 5,744 | 6,010 | 6,228 | 6,463 |
| Depreciation and amortisation | 4,226 | 4,360 | 4,952 | 5,360 |
| Metric (%) | FY2025 actual | FY2026 plan | FY2027 plan | FY2028 plan |
| Sales growth | 2.6 | 4.1 | 3.9 | 3.6 |
| Operating margin | 11.6 | 12.3 | 11.9 | 11.7 |
| EBITDA margin | 19.0 | 19.8 | 20.0 | 19.9 |
| Regional plan | FY2026 plan | FY2027 plan | FY2028 plan |
|---|---|---|---|
| Japan net sales (JPY bn) | 43.9 | 45.0 | 46.1 |
| Japan operating profit (JPY bn) | 4.5 | 4.7 | 4.9 |
| USA net sales (USD M) | 110.0 | 114.9 | 120.1 |
| USA operating profit (USD M) | 0.1 | 2.3 | 3.3 |
| China net sales (RMB M) | 637.5 | 665.3 | 695.0 |
| China operating profit (RMB M) | 192.5 | 193.6 | 177.0 |
| SE Asia net sales (JPY bn) | 6.2 | 6.8 | 7.4 |
| SE Asia operating profit (JPY bn) | 0.9 | 0.6 | 0.7 |
Source: [PRES-H1FY26]. FX assumption ¥145/US$ and ¥20.50/RMB. Note that the plan implies flat operating profit in FY2027–FY2028 as new-plant depreciation and Hoàng Anh goodwill (¥245M per year) land; it is a growth-investment phase, not a margin-expansion phase.
Source: [PRES-H1FY26]. The planned FY2028 drop in China profit and FY2027 drop in SE Asia profit reflect start-up depreciation at Pinghu and Enstek.
Products & Services
T. Hasegawa sells roughly 12,000 distinct flavours and fragrances per year, nearly all customer-specific formulations [PRES-H1FY26]. Pricing is negotiated per formula and volume and is not publicly disclosed for any product. The catalogue below is organised by business; only branded technologies and product lines that are publicly named are listed individually.
Flavour business (89.6% of FY2025 sales)
| Product line / brand | Description & capabilities | Target customers | Launch / latest | Source |
|---|---|---|---|---|
| Liquid compounded flavours | Water- and oil-soluble flavour formulations; highest-margin format for beverages | Beverage, dairy and confectionery makers in Japan, China, USA | Core since 1948 | [PRES-FY24], [MHLW-ITAKURA] |
| Emulsified flavours | Clouding and emulsified flavours for beverages and dairy | Beverage makers | — | [MHLW-ITAKURA] |
| Powdered flavours | Spray-dried and encapsulated flavours; powder sales in Malaysia doubled in FY2024; new powder facility at Suzhou slated for FY2027 | Instant noodle, seasoning, snack and powdered-drink makers (Asia focus) | Suzhou facility FY2027 | [PRES-FY24], [PRES-H1FY26] |
| Savoury / reaction flavours | Thermal-process and reaction flavours, seasonings | Snack, seasoning, instant noodle makers; US savoury | — | [PRES-H1FY26] |
| Sweet flavours (US) | Dairy, bakery, plant-based, fruit-filling and confectionery flavours from the Mission acquisition | US food manufacturers | Acquired Dec 2020 | [PREPFOODS] |
| ABELEI flavour line | Sweet brown, citrus, fruit and other liquid flavours | Midwest/East Coast US food, beverage, confectionery, dairy, nutrition | Acquired Sep 2024 | [PRES-FY24], [CBINSIGHTS] |
| BOOSTRACT® | Kokumi-enhancing flavour modifier adding richness and mouthfeel | Food and beverage formulators (USA/Japan) | Highlighted 2025 | [GCI-2025] |
| Cocoa Powder Replacer flavours | Flavours reducing dependence on volatile cocoa powder supply | US bakery and confectionery makers | 2024–2025 | [GCI-2025] |
| Japanese citrus portfolio | Eight Japanese citrus flavours launched for the US market | US beverage makers | 2,020 | [FBMEA] |
| HaseAroma (ハセアロマ) | Branded aroma line (detailed specifications not disclosed) | Food makers, Japan | — | [KABUTORE] |
| Marukajiri Flavor (まるかじりフレーバー) | "Whole-fruit-bite" flavour concept reproducing fresh fruit character (specifications not disclosed) | Beverage and confectionery makers, Japan | — | [KABUTORE] |
| Chef Aroma (シェフアロマ) | Cooking-aroma flavours (specifications not disclosed) | Prepared-food and seasoning makers | — | [KABUTORE] |
| Antioxidants / functional ingredients | Food antioxidants and functional materials | Food makers | — | [KABUTORE] |
| Raw-material replacement flavours | Flavours and ingredients that substitute scarce or costly food raw materials (SDG positioning) | Japanese food makers | Strategic focus FY2024–FY2026 | [PRES-H1FY26] |
| Plant-based protein flavours | Masking and flavouring for plant-based foods; capital and business alliance with DAIZ Corporation | Alt-protein makers | Alliance referenced FY2024 | [PRES-FY24] |
| Health and medical food flavours | Flavours for health foods and medical foods | Healthcare food makers | New-sector focus | [PRES-H1FY26] |
| Natural extracts | Supercritical CO2 and conventional extracts | Internal use and food makers | CO2 plant since 1989 | [HIST] |
| Processed fruit / nut materials | Fruit processing and nut products (FC division of Hasegawa Business Service) | Confectionery and bakery makers | Fruit plant since 2001 | [HIST], [PRES-FY24] |
| Natural colourants | Natural colour products | Food makers | — | [MHLW-ITAKURA] |
| Feed flavours | Animal feed flavour department established 1968 | Feed makers | 1,968 | [HIST] |
| Vietnamese flavour line (Hoàng Anh) | Sweet flavours for dairy and beverages; savoury flavours for instant noodles; food ingredients | Vietnamese beverage, dairy, noodle makers and Japanese companies in Vietnam | Acquired Nov 2025 | [TANSHIN-FY25] |
Fragrance business (10.4% of FY2025 sales)
| Product line | Description | Target customers | Source |
|---|---|---|---|
| Fine fragrance and cosmetic fragrances | Compounded fragrances for cosmetics and perfumes | Japanese cosmetics houses | [PRES-H1FY26] |
| Toiletry and household fragrances | Shampoo, detergent and household-product fragrances | Toiletry makers (Japan, China) | [PRES-H1FY26] |
| Odour-masking and comfort fragrances | Fragrances addressing everyday malodour and "fragrance discomfort" (scent sensitivity) | Household and personal-care makers | [PRES-H1FY26] |
| Environmentally friendly fragrances | Lower-impact fragrance formulations | Japanese brand owners | [PRES-H1FY26] |
| Body-care fragrances (SE Asia) | Exported from Japan | Southeast Asian body-care makers | [PRES-H1FY26] |
| Aroma chemicals (captive) | Synthesised aroma chemicals used mainly in-house | Internal | [PRES-H1FY26] |
Fragrance sales returned to double-digit growth in H1 FY2026 (+11.8% YoY to ¥4,595M) after falling 3.9% in FY2025 [PRES-H1FY26].
Financial Narrative
Sources: consolidated figures from [TANSHIN-FY25] and [YUHO-FY25] for FY2024–FY2025, and from the Securities Report five-year summary, [ENVALITH] and [SA-BS]/[SA-CF] (S&P Global data) for FY2021–FY2023. Japanese GAAP; JPY millions unless stated.
Income statement
EBITDA = operating profit + depreciation (including amortisation of customer-related assets) + goodwill amortisation, per company definition [PRES-H1FY26]; FY2021–FY2024 values from [ENVALITH] and [PRES-FY24].
Revenue CAGR FY2021–FY2025: 7.2% (analyst calc.). Ten-year (FY2015–FY2025) sales CAGR is 4.5% and net profit CAGR 8.6% [IRBANK].
Commentary. Four consecutive record sales years reflect three drivers: (1) FX — yen depreciation added ¥2,159M to FY2024 sales alone [PRES-FY24]; (2) M&A — Mission (FY2021) and ABELEI (FY2025); and (3) organic gains in China and Japanese beverages. Gross margin has been resilient in a 39.6–41.4% band; the FY2023 dip reflects raw-material inflation, and the FY2024 recovery a richer mix of liquid flavours [PRES-FY24]. The FY2025 inflection was in SG&A, up 7.7% on personnel costs, ABELEI goodwill amortisation (goodwill amortisation rose from ¥982M to ¥1,195M) and PMI costs, cutting operating margin by 1.5 points [TANSHIN-FY25]. Net margin has drifted lower because FY2021–FY2022 were flattered by large gains on sale of cross-held shares (¥2,265M and ¥2,230M), which have tapered (¥814M in FY2025) [ENVALITH], [TANSHIN-FY25]. The effective tax rate is stable at 28–30%.
Balance sheet
Interest-bearing liabilities are derived from the company's disclosed "interest-bearing debt to operating cash flow" ratio (3.9%, 18.5%, 10.0%, 11.5% for FY2022–FY2025) and consist of lease obligations; the group has no bank borrowings [TANSHIN-FY25]. FY2024 goodwill/intangibles are shown as restated by the company; S&P data shows the provisional figures (goodwill ¥9,855M). FY2021 equity ratio is derived (net assets ÷ total assets).
Commentary. The balance sheet is ultra-conservative: equity funds 83.5% of assets, net cash equals roughly 25% of the current market capitalisation, and investment securities (cross-shareholdings) of ¥10.7bn are being reduced toward under 10% of net assets [PRES-FY24]. Intangibles have grown with US M&A to 16% of total assets. Working capital is heavy (≈82% of sales), reflecting long inventory cycles for natural raw materials and Japanese trade-credit norms.
Cash flow
Sources: [SA-CF], [TANSHIN-FY25], [PRES-FY24], [TANSHIN-FY21]. FY2021 acquisition outflow relates to Mission (closed 29 Dec 2020). FCF here is an analyst definition; S&P's FCF (OCF less PP&E capex only) is ¥7,408M, ¥4,399M, ¥5,207M, ¥10,809M and ¥8,315M respectively.
Commentary. Cash conversion is volatile because of working-capital swings (–¥2.1bn in FY2022 inventory build; +¥2.5bn release in FY2024). Average FCF of ≈¥6.4bn over five years comfortably covers ordinary dividends but not M&A plus the new ¥36.8bn three-year capex plan (FY2026–FY2028), which will draw on the ≈¥36bn cash reserve [PRES-H1FY26]. FY2025 was the first year since FY2021 with meaningful buybacks (¥2.24bn, including a ToSTNeT-3 off-floor purchase in August 2025) [TANSHIN-FY25], [KABUTORE].
Ratios
ROE (FY2024–FY2025) and ROA as reported [TANSHIN-FY25], [ENVALITH]; all other ratios are analyst calculations. FY2021 net debt/EBITDA assumes negligible lease debt. The company's own interest coverage (OCF ÷ interest paid) was 1,826.6x, 1,153.2x, 571.0x and 508.3x for FY2022–FY2025 [TANSHIN-FY25].
Commentary. Returns are structurally constrained by excess capital: ROIC excluding cash is ~7%, and ROE is diluted further by the ¥36.9bn cash and securities pile. The cash conversion cycle improved by ~24 days between FY2023 and FY2025, mainly via lower DIO. Leverage metrics are irrelevant to credit risk; the relevant risk is capital misallocation, which management has partly answered with the DOE ≥3% dividend policy and buybacks.
Interim FY2026 performance
Sources: [PRES-H1FY26], [TANSHIN-9MFY25], [FILINGREADER-Q3FY26], [RTT-Q3FY26]. 9M FY2026 EPS was ¥155.58 versus ¥130.79 (the prior-year comparator matches the prior-year diluted figure; basic 9M FY2025 EPS was ¥131.46 — basis of the FY2026 figure should be checked against the Tanshin).
Q3 FY2026 is derived (9M less H1). Q3 sales rose ≈16.3% and operating profit ≈21.3% versus Q3 FY2025 (¥18,724M / ¥2,729M) [PRES-H1FY26]. 9M progress against full-year guidance is 77.6% (sales), 83.1% (operating profit) and 86.5% (net profit), versus FY2025 9M progress of 74.2% and 85.1% for sales and operating profit, supporting management's stated aim to finish above guidance [PRES-H1FY26].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Metric (JPY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Japan external sales | — | 39,543 | 39,783 |
Japan total sales incl. inter-segment | — | 42,366 | 42,549 |
Japan segment profit | — | 4,947 | 3,789 |
Asia external sales | — | 16,971 | 17,826 |
Asia total sales incl. inter-segment | — | 17,140 | 18,020 |
Asia segment profit | — | 4,045 | 4,892 |
USA external sales | — | 15,130 | 15,885 |
USA total sales incl. inter-segment | — | 15,342 | 16,015 |
USA segment profit | — | 332 | -286 |
Consolidated net sales | 64,874 | 71,645 | 73,495 |
Consolidated operating profit | 7,507 | 9,371 | 8,515 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2024 | FY2025 |
|---|---|---|
Japan margin on total segment sales | 11.7 | 8.9 |
Asia margin on total segment sales | 23.6 | 27.1 |
USA margin on total segment sales | 2.2 | -1.8 |
Japan share of external sales | 55.2 | 54.1 |
Asia share of external sales | 23.7 | 24.3 |
USA share of external sales | 21.1 | 21.6 |
Japan external sales YoY growth | — | 0.6 |
Asia external sales YoY growth | — | 5.0 |
USA external sales YoY growth | — | 5.0 |
Segment Assets & Liabilities and Revenue by Segment
| Metric (JPY Mn) | FY2024 | FY2025 |
|---|---|---|
Japan segment assets | 117,579 | 119,086 |
Asia segment assets | 27,614 | 32,858 |
USA segment assets | 38,614 | 39,977 |
Japan depreciation | 1,837 | 1,851 |
Asia depreciation | 808 | 802 |
USA depreciation | 1,392 | 1,572 |
Japan capex (PP&E + intangibles) | 2,051 | 2,506 |
Asia capex (PP&E + intangibles) | 688 | 1,551 |
USA capex (PP&E + intangibles) | 919 | 1,105 |
Goodwill amortisation Asia | 171 | 45 |
Goodwill amortisation USA | 811 | 1,149 |
Unamortised goodwill USA (year-end) | 8,104 | 7,306 |
Revenue by Segment — Parent (Japan) net sales
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Parent (Japan) net sales (JPY Mn) | 39,711 | 42,366 | 42,543 |
Parent (Japan) operating profit (JPY Mn) | 4,538 | 4,915 | 3,937 |
US subsidiary net sales (JPY Mn) | 12,720 | 15,146 | 15,896 |
US subsidiary operating profit (JPY Mn) | -168 | 330 | -288 |
US subsidiary net sales (USD Mn) | 91.5 | 100.6 | 106.4 |
US subsidiary operating profit (USD Mn) | -1.2 | 2.1 | -1.9 |
China subsidiaries net sales (CNY Mn) | 542.3 | 576.3 | 608.6 |
China subsidiaries operating profit (CNY Mn) | 139.2 | 163.1 | 190.7 |
China subsidiaries net sales (JPY Mn) | 10,673 | 12,009 | 12,586 |
China subsidiaries operating profit (JPY Mn) | 2,739 | 3,398 | 3,944 |
Malaysia subsidiary net sales (JPY Mn) | 1,686 | 2,130 | — |
Malaysia subsidiary operating profit (JPY Mn) | 279 | 419 | — |
Southeast Asia incl. Japan exports net sales (JPY Bn) | 4.0 | 4.6 | 4.9 |
Southeast Asia operating profit (JPY Bn) | 0.6 | 0.7 | 0.8 |
Revenue by Segment and Revenue by Segment (%)
| Metric (JPY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Flavor sales | 57,075 | 63,669 | 65,828 |
Fragrance sales | 7,799 | 7,975 | 7,666 |
Flavor share of sales (%) | 88.0 | 88.9 | 89.6 |
Flavor YoY growth (%) | — | 11.6 | 3.4 |
Fragrance YoY growth (%) | — | 2.3 | -3.9 |
Revenue by Segment (9M FY2026)
| Metric (JPY Mn) | 9M FY2026 |
|---|---|
Japan segment sales | 33,023 |
Asia segment sales | 14,812 |
USA segment sales | 13,829 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 55,755 | 62,398 | 64,874 | 71,645 | 73,495 |
Cost of sales (JPY Mn) | 33,106 | 36,776 | 39,185 | 42,001 | 43,147 |
Gross profit (JPY Mn) | 22,648 | 25,622 | 25,689 | 29,643 | 30,347 |
SG&A (JPY Mn) | 15,788 | 17,570 | 18,181 | 20,272 | 21,832 |
Operating profit (JPY Mn) | 6,859 | 8,051 | 7,507 | 9,371 | 8,515 |
EBITDA company definition (JPY Mn) | 10,617 | 12,281 | 12,119 | 14,391 | 13,938 |
Ordinary profit (JPY Mn) | 7,466 | 9,075 | 8,185 | 9,723 | 9,288 |
Pre-tax profit (JPY Mn) | 9,692 | 11,267 | 9,322 | 10,170 | 9,794 |
Net profit attributable to owners (JPY Mn) | 6,763 | 8,007 | 6,671 | 7,201 | 6,921 |
EPS basic (JPY) | 163.63 | 194.65 | 162.16 | 175.04 | 169.50 |
EPS diluted (JPY) | — | — | — | 174.27 | 168.63 |
Dividend per share (JPY) | 55 | 61 | 61 | 70 | 74 |
Payout ratio (%) | 33.6 | 31.3 | 37.6 | 40.0 | 43.7 |
Margin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 40.6 | 41.1 | 39.6 | 41.4 | 41.3 |
Operating margin | 12.3 | 12.9 | 11.6 | 13.1 | 11.6 |
EBITDA margin | 19.0 | 19.7 | 18.7 | 20.1 | 19.0 |
Net margin | 12.1 | 12.8 | 10.3 | 10.1 | 9.4 |
Net sales YoY growth | 11.1 | 11.9 | 4.0 | 10.4 | 2.6 |
SG&A to sales | 28.3 | 28.2 | 28.0 | 28.3 | 29.7 |
Balance Sheet and Per-Share Data
| Metric (JPY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 120,945 | 133,553 | 139,125 | 144,504 | 147,151 |
Cash and deposits | 19,037 | 20,351 | 25,699 | 27,396 | 34,854 |
Short-term securities | 3,999 | 8,999 | 7,000 | 6,997 | 2,000 |
Cash and short-term securities | 23,036 | 29,350 | 32,699 | 34,393 | 36,854 |
Short-term debt (bank) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (bank) | 0 | 0 | 0 | 0 | 0 |
Interest-bearing liabilities incl. leases (derived) | — | 312 | 1,482 | 1,395 | 1,293 |
Net cash (derived) | — | 29,038 | 31,217 | 32,998 | 35,561 |
Net assets | 98,301 | 111,017 | 116,319 | 119,681 | 123,324 |
Goodwill | 6,043 | 6,815 | 6,060 | 8,150 | 7,306 |
Other intangibles incl. customer relationships | 10,670 | 13,379 | 13,564 | 14,573 | 16,210 |
Goodwill and intangibles | 16,713 | 20,194 | 19,624 | 22,723 | 23,517 |
Inventories | 14,080 | 16,841 | 16,849 | 16,414 | 17,014 |
Trade receivables | 17,046 | 18,695 | 19,841 | 20,442 | 19,997 |
Working capital | 43,638 | 52,658 | 58,536 | 57,470 | 60,386 |
Retirement benefit liability | 7,314 | 7,442 | 7,516 | 7,480 | 6,578 |
Treasury shares (book) | 2,630 | 2,555 | 2,556 | 2,556 | 4,774 |
Book value per share (JPY) | 2,385.69 | 2,692.34 | 2,819.86 | 2,899.96 | 3,038.39 |
Equity ratio (%) | 81.3 | 82.9 | 83.4 | 82.6 | 83.5 |
Cash Flow
| Metric (JPY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | 9,980 | 8,001 | 8,012 | 13,947 | 11,247 |
Capex PP&E | 2,572 | 3,602 | 2,805 | 3,138 | 2,932 |
Capex intangibles | 166 | 523 | 703 | 818 | 1,700 |
Free cash flow (OCF less PP&E and intangibles capex) | 7,242 | 3,876 | 4,504 | 9,991 | 6,615 |
Acquisitions (net cash out) | 12,885 | 0 | 0 | 6,637 | 0 |
Dividends paid | 1,824 | 2,548 | 2,552 | 2,549 | 3,113 |
Share buybacks | 846 | 0 | 0 | 0 | 2,238 |
Total shareholder returns | 2,670 | 2,548 | 2,552 | 2,549 | 5,351 |
Depreciation and amortisation incl. goodwill | 3,758 | 4,230 | 4,612 | 5,020 | 5,421 |
Cash and equivalents at year-end | 18,863 | 27,425 | 29,957 | 31,952 | 31,267 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 7.1 | 7.7 | 5.9 | 6.1 | 5.7 |
ROA net income basis (%) | 5.6 | 6.0 | 4.8 | 5.0 | 4.7 |
ROIC NOPAT on period-end invested capital (%) | 6.4 | 7.0 | 6.3 | 7.7 | 6.9 |
Current ratio (x) | 4.76 | 4.95 | 5.83 | 4.89 | 5.13 |
Debt to equity (x) | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Net debt to EBITDA (x) | -2.17 | -2.36 | -2.58 | -2.29 | -2.55 |
Interest coverage EBIT to interest (x) | 857 | 1,150 | 1,072 | 390 | 387 |
Asset turnover sales to year-end assets (x) | 0.46 | 0.47 | 0.47 | 0.50 | 0.50 |
DSO (days) | 111.6 | 109.4 | 111.6 | 104.1 | 99.3 |
DIO (days) | 155.2 | 167.1 | 156.9 | 142.6 | 143.9 |
DPO (days) | 55.1 | 61.6 | 50.5 | 55.0 | 49.2 |
Cash conversion cycle (days) | 211.7 | 214.9 | 218.0 | 191.7 | 194.0 |
Income Statement
| Metric (JPY Mn) | H1 FY2025 | H1 FY2026 | 9M FY2025 | 9M FY2026 |
|---|---|---|---|---|
Net sales | 35,823 | 37,585 | 54,548 | 59,355 |
Operating profit | 4,518 | 4,528 | 7,247 | 7,838 |
Ordinary profit | 4,924 | 4,936 | 7,779 | 8,455 |
Net profit attributable | 3,359 | 3,749 | 5,378 | 6,331 |
EBITDA | 7,235 | 7,347 | — | — |
Key Financials
| Metric (JPY Mn) | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|
Quarterly net sales | 17,793 | 19,793 | 21,770 |
Quarterly operating profit | 1,568 | 2,960 | 3,310 |
Revenue by Region
| Region (JPY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Japan | — | 36,928 | 37,075 |
China | — | 12,031 | 12,493 |
Other Asia | — | 7,531 | 7,850 |
USA | — | 14,080 | 14,829 |
Others | — | 1,074 | 1,246 |
Total | 64,874 | 71,645 | 73,495 |
Revenue by Region (%) and Region Margins & Growth (%)
| Region (%) | FY2024 | FY2025 |
|---|---|---|
Japan share | 51.5 | 50.4 |
China share | 16.8 | 17.0 |
Other Asia share | 10.5 | 10.7 |
USA share | 19.7 | 20.2 |
Others share | 1.5 | 1.7 |
Japan YoY growth | — | 0.4 |
China YoY growth | — | 3.8 |
Other Asia YoY growth | — | 4.2 |
USA YoY growth | — | 5.3 |
Others YoY growth | — | 16.0 |
Revenue by Region (%)
| Metric (%) | FY2023 | FY2024 | FY2025 | FY2026 plan | FY2027 plan | FY2028 plan |
|---|---|---|---|---|---|---|
Overseas share of consolidated net sales | 46.5 | 48.5 | 49.6 | 50.3 | 50.5 | 51.2 |
Locations
| Location (JPY Mn) | FY2024 | FY2025 |
|---|---|---|
Japan | 18,889 | 18,797 |
China | 7,221 | 6,816 |
Other Asia | 1,278 | 1,791 |
USA | 8,977 | 9,589 |
Share Price
| Metric (JPY) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Fiscal year-end share price (derived) | 2,999 | 3,050 | 3,273 | 2,914 |
Performance Details
| Performance | Value |
|---|---|
Price on 1 Oct 2026 | ¥3,350 [KABUYOHO-OCT26] |
1-year (30 Sep 2025 → 1 Oct 2026, derived) | ≈ +15% |
3-year (30 Sep 2023 → 1 Oct 2026, derived) | ≈ +10% |
2026 low | ¥2,698 (9 Feb 2026) [TRADERS] |
Recent high | ¥3,480 (18 Sep 2026) [KABUTORE] |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | ¥143.1bn | [KABUYOHO-OCT26] |
P/E (company FY2026E) | 18.6x | [KABUYOHO-OCT26] |
P/B (actual) | 1.01x | [KABUYOHO-OCT26] |
Dividend yield (FY2026E ¥100) | 2.99% | [KABUYOHO-OCT26] |
EV (derived: market cap less ≈¥35bn net cash) | ≈¥108bn | Analyst calc. |
EV/EBITDA FY2025 actual | ≈7.8x | Analyst calc. |
EV/EBITDA FY2026E (company) | ≈7.1x | Analyst calc. |
EV/Sales FY2026E | ≈1.4x | Analyst calc. |
Income Statement (Consensus FY2026 (1 Oct 2026)–Company FY2026 guidance)
| Metric (JPY Mn) | Company FY2026 guidance | Consensus FY2026 (1 Oct 2026) |
|---|---|---|
Net sales | 76,500 | 78,150 |
Operating profit | 9,430 | 9,628 |
Ordinary profit | 10,050 | 10,373 |
Net profit | 7,320 | 7,698 |
Per-Share Data and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (JPY) | 22 | 29 | 30 | 31 | 37 |
Year-end DPS (JPY) | 33 | 32 | 31 | 39 | 37 |
Annual DPS (JPY) | 55 | 61 | 61 | 70 | 74 |
Payout ratio (%) | 33.6 | 31.3 | 37.6 | 40.0 | 43.7 |
DOE (%) | 2.4 | 2.4 | 2.2 | 2.4 | 2.4 |
Dividends & Capital Returns
| Metric (JPY Mn) | FY2019 | FY2021 | FY2025 |
|---|---|---|---|
Share buybacks | 1,565 | 846 | 2,238 |
Capital Markets
| Item | Status |
|---|---|
Moody's / S&P / Fitch | Not rated (no public rating identified) |
R&I / JCR (domestic) | No public rating identified |
Debt maturity profile | Not applicable — interest-bearing liabilities are lease obligations of ≈¥1.3bn (derived) |
Analyst Conclusions
Management guidance (FY2026, unchanged since 7 Nov 2025)
Net sales ¥76,500M (+4.1%), operating profit ¥9,430M (+10.7%), ordinary profit ¥10,050M (+8.2%), net profit ¥7,320M (+5.8%), EPS ¥180.97, DPS ¥100. Drivers: Japan margin recovery to 10.3%, US breakeven after one-off PMI costs, China growth (+4.8% RMB), and Hoàng Anh consolidation [TANSHIN-FY25], [QA-FY25], [PRES-H1FY26]. At 9M, progress (sales 77.6%, OP 83.1%, NP 86.5%) points to a modest beat, consistent with consensus.
Consensus growth expectations
Consensus implies FY2026 sales growth of 6.3% and net profit growth of 11.2% versus FY2025 [KABUYOHO-OCT26]. Management's rolling plan implies only 3.6–3.9% sales growth and flat operating profit in FY2027–FY2028 as new plants depreciate [PRES-H1FY26].
Bull case
-
Capacity-led Asian growth. Pinghu (2x China capacity) and Enstek (+20–30%) come online in FY2027, attached to a China business earning ~30% operating margins and an SE Asia business planned to grow ~25% in FY2026 [PRES-FY24], [PRES-H1FY26].
-
US turnaround optionality. The US subsidiary already earns ~16–18% EBITDA margins; the operating loss is largely acquisition amortisation (US$13.1M per year). Delivering the FY2028 target of US$3.3M OP — or beating it — adds directly to group profit [PRES-H1FY26].
-
Capital-return re-rating. DOE ≥3%, a 35% DPS increase and resumed buybacks, plus ≈¥35bn net cash (~25% of market cap), give a credible path toward higher ROE and a P/B above 1.0x [TANSHIN-FY25], [KABUYOHO-OCT26].
Bear case
-
Profit stagnation embedded in the plan. Management guides operating profit essentially flat (¥9.4–9.6bn) through FY2028 despite ¥36.8bn of capex; ROE is unlikely to move far from ~6% without bigger capital returns [PRES-H1FY26].
-
China normalisation. Customer multi-sourcing, product discontinuations and a planned decline in China operating margin to 25.5% by FY2028 threaten the group's largest profit pool [PRES-H1FY26].
-
M&A track record. Three US acquisitions (FIH, Mission, ABELEI) have not yet delivered sustained US operating profit; another ¥3.7bn of goodwill (Hoàng Anh) adds impairment exposure if PMI disappoints [TANSHIN-FY25], [PRES-H1FY26].
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Early Nov 2026 | FY2026 results versus guidance; FY2027 guidance; updated rolling plan FY2027–FY2029; year-end DPS confirmation |
| Nov 2026 | Any new buyback authorisation (PBR condition) |
| Dec 2026 | Hoàng Anh PMI completion; AGM (board refresh, chair/CEO structure) |
| FY2027 | Start-up of Pinghu, Suzhou powder line and Enstek plant; start-up costs |
| Ongoing | US quarterly operating profit turning positive (targeted from Q3 FY2026); Japanese beverage volumes over the summer season; RMB and US$ rates vs ¥145 assumption; Middle East raw-material costs; cross-shareholding sales |
Analyst verdict
T. Hasegawa is a high-quality, under-levered, under-earning franchise. On the quality side, the evidence is unambiguous: it is the most profitable listed Japanese flavour house by a wide margin (11.6% operating margin versus 3.6% at its larger domestic rival), it owns a China business with returns that would be the envy of global majors, and it funds all growth and M&A internally while sitting on roughly ¥35bn of net cash. Four consecutive record-sales years and 7% revenue CAGR since FY2021 show the commercial engine is intact, and the Q3 FY2026 print (operating profit up ~21% in the quarter) suggests the FY2025 profit dip was cyclical and one-off rather than structural.
The problem is translation of quality into shareholder returns. ROE has languished between 5.7% and 7.7% for five years, and management's own rolling plan holds operating profit flat through FY2028 as the group digests a ¥36.8bn capex wave across three new plants and an ERP rebuild. The US platform — built through three acquisitions — remains marginal at the operating line, and the China profit pool, the group's crown jewel, faces customer multi-sourcing and a planned margin decline.
The investment case therefore hinges on capital allocation rather than operations. The November 2025 shift to a DOE ≥3% dividend floor and the return of buybacks are genuine steps; at ~7x EV/EBITDA, ~18.6x forward P/E and P/B of ~1.0x, the market is pricing the company as a low-return bond proxy. If management couples the new plants with a disciplined US turnaround and continues to recycle excess cash and cross-shareholdings, a re-rating toward the ¥4,175 consensus target is plausible. Absent that, the stock is likely to remain a steady, 3%-yielding compounder rather than a growth story. Overall stance: constructive on quality and downside protection; neutral-to-positive on upside, contingent on capital-efficiency delivery.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Born / age* | Director since | Background | Shares held |
|---|---|---|---|---|---|
Takao Umino | Representative Director, Chairman & CEO | 1947 / 79 | Dec 2008 | Mitsui Bank; President of Sakura Card (now SMBC Card); joined 2008; President 2017–2024; Chairman since Oct 2024; Chairman of THUSA and Hoàng Anh | 16,700 |
Kenji Hasegawa | Representative Director, President & COO | 1962 / 64 | Dec 2023 | Mizkan group (legal head; President of Mizkan Holdings from 2014); outside director of Unizo Holdings; joined 2020; President since Oct 2024 | 2,800 |
Tetsuya Nakamura | Director & Senior Managing Executive Officer (Research, Production; Business Solution Division head) | 1959 / 67 | Dec 2021 | Joined 1982; head of Technical Research Institute and Central Research Institute | 8,400 |
Masayasu Amaike | Director & Managing Executive Officer (Sales, Marketing) | 1961 / 65 | Dec 2024 | Joined 1984; Fragrance Institute head; Shanghai GM; International Division head | 5,000 |
Masahiro Nishimoto | Director & Executive Officer (Research) | 1966 / 60 | Dec 2025 | Joined 1988; Flavor Institute; Quality Assurance; Central Research Institute head | 13,400 |
Yukiko Iwasaki | Director & Executive Officer (Corporate Management) | 1968 / 58 | Dec 2025 | Joined 1988; HR and General Affairs head | 10,100 |
Shingo Daimon | Outside Director (independent) | 1946 / 80 | Dec 2015 | Toppan Printing managing director, international; Toppan USA CEO | 0 |
Akiko Izumi | Outside Director (independent) | 1961 / 64 | Dec 2021 | Economic journalist, CFP®, HR consultant; founder of Platinum Concierge | 0 |
Paul Dupuis | Outside Director (independent) | 1968 / 58 | Dec 2023 | Randstad India MD & CEO; Randstad Japan Chairman & CEO | 0 |
Yuichi Tada | Outside Director (independent) | 1959 / 67 | Dec 2024 | Brother Industries senior managing director; head of Brother Europe | 0 |
Board of Directors — Takehiro Matsumoto
| Name | Role | Background | Term to |
|---|---|---|---|
Takehiro Matsumoto | Full-time Audit & Supervisory Board Member | SMBC (New York, Canada, Malaysia shared services); internal audit head | AGM 2027 |
Tomonori Arita | Outside (independent) | Former Superintending Prosecutor (Fukuoka High Public Prosecutors Office); attorney | AGM 2027 |
Kazuhito Yamamura | Outside (independent) | FUJIFILM director and CFO-track; President, FUJIFILM Holdings America | AGM 2027 |
Maki Suzuki | Outside (independent) | Attorney (Japan, New York); M&A/corporate law | AGM 2027 |
Governance Overview
| Attribute | Value |
|---|---|
Directors | 10 (4 independent outside = 40%) |
Audit & Supervisory Board | 4 (3 independent outside) |
Women among directors and A&SB members | 3 of 14 (21.4%) post-AGM |
Chair / CEO separation | Not separated — the Chairman is also CEO; the President is COO |
Director term | 1 year |
Executive officers | 13 executive officers, 4 group executive officers and 2 fellows (post-AGM) |
Key overseas executive | Thomas Damiano — Managing Group Executive Officer; President, CEO and CFO of THUSA; President of ABELEI |
Board & Management Changes
| Date | Change |
|---|---|
Dec 2014 | Tokujiro Hasegawa from President to Chairman; Takahiko Kondo appointed President |
Nov 2017 | Takao Umino appointed President & COO |
Oct 2024 | Umino to Chairman & CEO; Kenji Hasegawa to President & COO |
Oct 2025 | Kenji Hasegawa assumes oversight of Corporate Strategy and Corporate Management divisions |
Dec 2025 | Nishimoto and Iwasaki join the board; Chino and M. Nakamura leave (inferred) |
Major Shareholders
| Holder category (30 Sep 2025) | % of shares |
|---|---|
Foreign corporations and individuals | 42.47 |
Other domestic corporations | 23.72 |
Individuals and others (incl. treasury) | 19.10 |
Financial institutions | 13.59 |
Securities companies | 1.11 |
Major Shareholders by Major Holder
| Major holder | Stake | Basis / date |
|---|---|---|
Hasegawa Totaro Shoten (founding-family asset company) | 16.36% (6.62M shares) | Register, 30 Sep 2025 |
Massachusetts Financial Services Company (MFS) | 6.27% | Large shareholding change report, Jun 2025 |
Burgundy Asset Management | 2.97% | Change report (below 5%), Aug 2025 |
Treasury shares | 5.29% (2.26M shares) | 30 Sep 2025 |
Competitive Landscape
Market Share by Competitor
| Rank | Company | Country | F&F sales (USD Mn) | Share of top-10 (%) |
|---|---|---|---|---|
| 1 | Givaudan | Switzerland | 9,041 | 22.1 |
| 2 | IFF (Nourish + Scent only) | USA | 8,238 | 20.2 |
| 3 | dsm-firmenich (ex-HNC) | Switzerland/Netherlands | 7,820 | 19.1 |
| 4 | Symrise | Germany | 5,582 | 13.7 |
| 5 | ADM (Human Nutrition) | USA | 4,187 | 10.2 |
| 6 | Mane SA | France | 2,278 | 5.6 |
| 7 | Takasago | Japan | 1,494 | 3.7 |
| 8 | Robertet SA | France | 934 | 2.3 |
| 9 | Sensient Technologies (F&F) | USA | 787 | 1.9 |
| 10 | T. Hasegawa | Japan | 491 | 1.2 |
Market Share by Competitor by Company
| Company (anonymised by T. Hasegawa) | Share (%) | Prior year (%) |
|---|---|---|
Company T (consistent with Takasago) | 35.5 | 34.4 |
T. Hasegawa | 18.8 | 18.7 |
Company O | 10.5 | 10.9 |
Company G | 10.0 | 10.2 |
Company SI | 6.1 | 6.2 |
Company SO | 5.5 | 5.4 |
Others | 13.7 | 14.1 |
Competitors by Segment
| Segment / region | Key competitors |
|---|---|
Japan flavours | Takasago, Ogawa & Co., San-Ei Gen F.F.I., Givaudan, Firmenich (dsm-firmenich), IFF, Soda Aromatic |
Japan fragrances | Takasago, Givaudan, Firmenich, Symrise, IFF, Soda Aromatic |
USA flavours | Givaudan, IFF, dsm-firmenich, Symrise, ADM, Kerry, Sensient, McCormick Flavor Solutions, Mane, Takasago, numerous mid-sized private houses |
China | Global majors, Takasago, Huabao, Apple Flavor & Fragrance, many local houses |
Southeast Asia | Global majors, Mane, Takasago, Ogawa, local houses |
Peer Comparison FY2028
| Metric | T. Hasegawa (FY Sep-2025) | Takasago (FY Mar-2026) |
|---|---|---|
Net sales (JPY Mn) | 73,495 | 225,092 |
Flavor share (%) | 89.6 | 54.5 |
Fragrance share (%) | 10.4 | 33.7 |
Aroma chemicals share (%) | 0.0 | 11.2 |
Gross margin (%) | 41.3 | 32.4 |
Operating margin (%) | 11.6 | 3.6 |
R&D to sales (%) | 7.8 | — |



